aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update

Provided By GlobeNewswire

Last update: Nov 9, 2023

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024.

Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD initiated patient dosing.